Saturday, April 10, 2021
- Advertisement -
Home World Scientists who manufacture AstraZeneca vaccines begin to make super gonorrhea vaccines

Scientists who manufacture AstraZeneca vaccines begin to make super gonorrhea vaccines – Scientists from the University of Oxford who are working with AstraZeneca in the manufacture of the Covid-19 vaccine are trying to develop a similar product, namely a vaccine to treat gonorrhea.

To develop a sexually transmitted disease vaccine, CARB-X’s global antibacterial funding program provided the Oxford Jenner Institute with USD 2 million (over IDR 29 billion).

The development of this vaccine comes after concerns that the bacterial infection cannot be treated with antibiotics.

Health experts, reported Insider, said the increasing use of antibiotics as prescription drugs over the years has caused the gonorrhea bacteria Neisseria gonorrhoeae to mutate and become resistant to common treatments.

Also Read:
First in the World, Russia Launches COVID-19 Vaccine for Animals

- Advertisement -

Antibiotics are also used for Covid-19 patients who experience chest infections and pneumonia.

Gonorrhea illustration (Shutterstock)
Gonorrhea illustration (Shutterstock)

Thus, this dependence on use ultimately made the mutated version of gonorrhea difficult to counter, which scientists refer to as ‘super gonorrhea’.

This can make it difficult for people with gonorrhea to get effective treatment, even if the case of infection or transmission from person to person does not get worse.

In 2007, the Centers for Disease Control and Prevention (CDC) recommended a combination of the two antibiotics ceftriaxone and azithromycin because the previous drug ciprofloxacin had made gonorrhea bacteria resistant.

Then, in 2018, experts found that STIs had become resistant to azithromycin and advised doctors to use another antibiotic, ceftriaxone.

Also Read:
Azis Syamsuddin Requesting Acceleration of Domestic Vaccine Production

The Oxford scientists leading the cost of the super gonorrhea vaccine are hoping to reach the clinical trial phase by 2024.



Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments